Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial
Definium Therapeutics Inc. surged in pre-market trading after the company said its LSD-based DT120 tablet hit the main target in a late-stage depression trial. The New York biotech traded at $40.19 on Public.com at 9:00 a.m. ET, up 64.2% from Friday’s close of $24.48. Nasdaq’s session hadn’t started yet, with the open set for 9:30 a.m. ET.